McGrath et al. used CRISPR/Cas9 in ESCs to disrupt NEUROG3, which is associated with permanent neonatal diabetes mellitus [138,139,140,141], and showed that NEUROG3 is required for human pancreatic endocrine cell development [142]. This evidence concerns the gene NEUROG3 and neonatal diabetes mellitus.